AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20122023 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 0
Study 17685710 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching before workout
Number of subjects: 30
Study 17685710 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching after workout
Number of subjects: 30
Study 16388091 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/d)
Number of subjects: 12
Study 16388091 — intervention group
Group type: COMPARATOR
Intervention: Control (without troglitazone)
Number of subjects: 12
Study 16388091 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone and Control
Number of subjects: 12
Study 12161056 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (n=116, preprandially three-times daily)
Number of subjects: 235
Study 12161056 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (n=119, preprandially once- or twice-daily)
Number of subjects: 235
Study 12161056 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 235
Study 9447854 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane without fentanyl
Number of subjects: 71
Study 9447854 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane without fentanyl
Number of subjects: 71
Study 9447854 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with 1.5 microg/kg fentanyl
Number of subjects: 71
Study 9447854 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with 1.5 microg/kg fentanyl
Number of subjects: 71
Study 9447854 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with 3 microg/kg fentanyl
Number of subjects: 71
Study 9447854 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with 3 microg/kg fentanyl
Number of subjects: 71
Study 9447854 — intervention group
Group type: COMPARATOR
Intervention: Desflurane and isoflurane without fentanyl
Number of subjects: 71
Study 7819058 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms three times a day for 5 days a week)
Number of subjects: 107
Study 7819058 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 107
Study 7819058 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 107
Study 2194053 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5mg of dibucaine with 0.05mg of buprenorphine (G-II)
Number of subjects: 50
Study 2194053 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5mg of dibucaine with 0.25mg of morphine (G-III)
Number of subjects: 50
Study 2194053 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5mg of dibucaine with 0.25mg of morphine and 0.2mg of naloxone (G-IV)
Number of subjects: 50
Study 2194053 — intervention group
Group type: COMPARATOR
Intervention: 7.5mg of dibucaine only (G-I)
Number of subjects: 50
Study 348378 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks
Number of subjects: 30
Study 348378 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks in hypercholesterolemic patients
Number of subjects: 30
Study 348378 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-aminosalicylic acid (PAS) 6 gm daily for 4 weeks in hypertriglyceridemia type IV patients
Number of subjects: 30
Study 31927569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral therapy for insomnia (CBTi) over 4 weeks (n=72)
Number of subjects: 145
Study 31927569 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (n=73)
Number of subjects: 145
Study 30986737 — intervention group
Group type: EXPERIMENTAL
Intervention: DROP programme (care management, optimised management of depression, psychoeducational programme)
Number of subjects: 328
Study 30986737 — intervention group
Group type: EXPERIMENTAL
Intervention: DROP programme
Number of subjects: 328
Study 30986737 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 328
Study 28649948 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) plus usual care
Number of subjects: 500
Study 28649948 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 500
Study 25771069 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and folic acid (10 mg enalapril, 0.8 mg folic acid)
Number of subjects: 20702
Study 25771069 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone (10 mg)
Number of subjects: 20702
Study 23585557 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) exposure therapy, n = 7
Number of subjects: 15
Study 23585557 — intervention group
Group type: COMPARATOR
Intervention: Imaginal Exposure (IE) therapy, n = 8
Number of subjects: 15
Study 21755820 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet adhesion assay (PADA) in AMI patients
Number of subjects: 104
Study 21755820 — intervention group
Group type: COMPARATOR
Intervention: Platelet adhesion assay (PADA) in SAP patients
Number of subjects: 104
Study 21755820 — intervention group
Group type: COMPARATOR
Intervention: Platelet adhesion assay (PADA) in control group
Number of subjects: 104
Study 21755820 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography and stent implantation
Number of subjects: 104
Study 18795264 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment with cognitive behavioral therapy
Number of subjects: 63
Study 18795264 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone treatment
Number of subjects: 63
Study 16757790 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritually based self-management tools
Number of subjects: 0
Study 11860403 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 40
Study 11860403 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 40
Study 10442205 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 12
Study 10442205 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 12
Study 10442205 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tramadol
Number of subjects: 12
Study 7568442 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence (16 hours)
Number of subjects: 20
Study 7568442 — intervention group
Group type: COMPARATOR
Intervention: No smoking abstinence
Number of subjects: 20
Study 1694236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and daunorubicin (course one) followed by standard-dose cytarabine and daunorubicin (course two)
Number of subjects: 102
Study 1694236 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine and doxorubicin (course one) followed by standard-dose cytarabine, daunorubicin, and thioguanine (course two)
Number of subjects: 102
Study 1694236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine-based chemotherapy and/or allogeneic bone marrow transplantation (BMT)
Number of subjects: 102
Study 1694236 — intervention group
Group type: EXPERIMENTAL
Intervention: ALP3 postremission chemotherapy regimen
Number of subjects: 102
Study 619938 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 0.2 mg intramuscularly
Number of subjects: 6
Study 619938 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (oral route)
Number of subjects: 6
Study 619938 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (intravenous route)
Number of subjects: 6
Study 619938 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (intramuscular route)
Number of subjects: 6
Study 619938 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger doses of Glycopyrronium
Number of subjects: 6
Study 619938 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium (sweat gland activity)
Number of subjects: 6
Study 29468701 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d allopurinol
Number of subjects: 73
Study 29468701 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d allopurinol
Number of subjects: 73
Study 29468701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 29468701 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who achieved primary endpoint
Number of subjects: 73
Study 27471786 — intervention group
Group type: EXPERIMENTAL
Intervention: STAND
Number of subjects: 9
Study 27471786 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK
Number of subjects: 9
Study 27471786 — intervention group
Group type: EXPERIMENTAL
Intervention: CYCLE
Number of subjects: 9
Study 27471786 — intervention group
Group type: COMPARATOR
Intervention: SIT
Number of subjects: 9
Study 26282359 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008
Study 26282359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study 26282359 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 1008
Study 26282359 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1008
Study 24418037 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (n = 50)
Number of subjects: 100
Study 24418037 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (n = 50)
Number of subjects: 100
Study 20497967 — intervention group
Group type: EXPERIMENTAL
Intervention: Matuzumab plus ECX (800 mg matuzumab weekly, epirubicin 50 mg/m², cisplatin 60 mg/m², capecitabine 1250 mg/m²)
Number of subjects: 72
Study 20497967 — intervention group
Group type: COMPARATOR
Intervention: ECX alone (epirubicin 50 mg/m², cisplatin 60 mg/m², capecitabine 1250 mg/m²)
Number of subjects: 72
Study 18456138 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant group
Number of subjects: 18
Study 18456138 — intervention group
Group type: COMPARATOR
Intervention: J-hook headgear group
Number of subjects: 18
Study 15920102 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) ingestion (6.4% wt/vol) during exercise
Number of subjects: 15
Study 15920102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) beverage ingestion during exercise
Number of subjects: 15
Study 12448067 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (n = 28; dose 25 to 100 mg)
Number of subjects: 54
Study 12448067 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (n = 26; dose 1 to 10 mg)
Number of subjects: 54
Study 12448067 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Atenolol vs Terazosin
Number of subjects: 54
Study 9607387 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 to 10 mg once daily (n = 55)
Number of subjects: 103
Study 9607387 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine SR 20 mg twice daily (n = 48)
Number of subjects: 103
Study 7883543 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enoxaparin administered 12 hours before surgery
Number of subjects: 40
Study 7883543 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 12 hours before surgery
Number of subjects: 40
Study 2244403 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg tid
Number of subjects: 74
Study 2244403 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg tid
Number of subjects: 74
Study 402206 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal orchiectomy followed by irradiation to the inguinal, iliac, lumbar para‐aortic, mediastinal and supraclavicular lymph nodes.
Number of subjects: 91
Study 402206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative irradiation to primary lymphatic pathways in association with bilateral retroperitoneal lymphadenectomy and elective irradiation to the mediastinum and supraclavicular regions.
Number of subjects: 91
Study 402206 — intervention group
Group type: COMPARATOR
Intervention: Both treatment methods (inguinal orchiectomy with irradiation and pre- and postoperative irradiation with lymphadenectomy)
Number of subjects: 91
Study 31074245 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally-invasive secondary cytoreductive surgery (MI-SCS)
Number of subjects: 20
Study 31074245 — intervention group
Group type: COMPARATOR
Intervention: Open secondary cytoreductive surgery (O-SCS)
Number of subjects: 20
Study 31074245 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cisplatin peritoneal Cmax
Number of subjects: 20
Study 31074245 — intervention group
Group type: COMPARATOR
Intervention: Lower cisplatin peritoneal Cmax
Number of subjects: 20
Study 28467880 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab (administered intravenously once every 3 weeks for a total of eight infusions)
Number of subjects: 88
Study 28467880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered intravenously once every 3 weeks for a total of eight infusions)
Number of subjects: 88
Study 28467880 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 88
Study 28467880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 26106097 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation of the fornix (200 Hz in 100 ms trains, five trains per second, 100 µs, 7 mA)
Number of subjects: 4
Study 26106097 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 4
Study 24477039 — intervention group
Group type: EXPERIMENTAL
Intervention: White-wheat bread low in dietary fiber
Number of subjects: 21
Study 24477039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread with whole-rye kernels
Number of subjects: 21
Study 24477039 — intervention group
Group type: EXPERIMENTAL
Intervention: White-wheat bread supplemented with wheat arabinoxylan
Number of subjects: 21
Study 24477039 — intervention group
Group type: EXPERIMENTAL
Intervention: White-wheat bread supplemented with oat β-glucan
Number of subjects: 21
Study 22805083 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine group (CMG) - treated with Chinese medicine according to syndrome differentiation for 48 weeks.
Number of subjects: 131
Study 22805083 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (WMG) - treated with donepezil at a dose of 5 mg once daily for 48 weeks.
Number of subjects: 131
Study 19910654 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (2.4 g/d; 2,000 mg EPA, 400 mg DHA)
Number of subjects: 23
Study 19910654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17301105 — intervention group
Group type: EXPERIMENTAL
Intervention: Home testing kit
Number of subjects: 403
Study 17301105 — intervention group
Group type: COMPARATOR
Intervention: Invitation to attend a medical clinic for testing
Number of subjects: 403
Study 15151941 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 560
Study 11190790 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative priming (cognitive inhibition)
Number of subjects: 0
Study 9845996 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling supervision group
Number of subjects: 0
Study 9845996 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 0
Study 8087446 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin and ceftazidime
Number of subjects: 166
Study 31018727 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using PICO, Smith & Nephew, St. Petersburg, FL
Number of subjects: 179
Study 31018727 — intervention group
Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 179
Study 31018727 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using PICO, Smith & Nephew, St. Petersburg, FL (after matching)
Number of subjects: 179
Study 31018727 — intervention group
Group type: COMPARATOR
Intervention: Standard dressings (after matching)
Number of subjects: 179
Study 30064450 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (2.5 g/day)
Number of subjects: 23
Study 30064450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 26937942 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O (nitrous oxide) inhalation
Number of subjects: 50
Study 26937942 — intervention group
Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 50
Study 23962976 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based psychosocial intervention
Number of subjects: 0
Study 23345635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (up to 12 mg/day for 20 weeks)
Number of subjects: 17
Study 23345635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 17
Study 20484125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes TeleCare (remote comprehensive diabetes self-management education)
Number of subjects: 0
Study 20484125 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19707287 — intervention group
Group type: EXPERIMENTAL
Intervention: Various antithrombotic regimens (specific regimens not detailed)
Number of subjects: 0
Study 19707287 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant and antiplatelet agents (specific agents not detailed)
Number of subjects: 0
Study 16813591 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 16813591 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 16813591 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for rectal cancer
Number of subjects: 0
Study 16813591 — intervention group
Group type: COMPARATOR
Intervention: Fast-track open surgery
Number of subjects: 0
Study 15566681 — intervention group
Group type: COMPARATOR
Intervention: EMBE
Number of subjects: 49
Study 15566681 — intervention group
Group type: EXPERIMENTAL
Intervention: EMBE and after-loading treatment
Number of subjects: 49
Study 15566681 — intervention group
Group type: EXPERIMENTAL
Intervention: EMBE and RFA
Number of subjects: 49
Study 15566681 — intervention group
Group type: EXPERIMENTAL
Intervention: EMBE and PCS
Number of subjects: 49
Study 11003070 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Auditory Brainstem Response (AABR)
Number of subjects: 105
Study 11003070 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion‐Product Otoacoustic Emissions
Number of subjects: 105
Study 11003070 — intervention group
Group type: EXPERIMENTAL
Intervention: Click‐Evoked Otoacoustic Emissions
Number of subjects: 105
Study 11003070 — intervention group
Group type: COMPARATOR
Intervention: All tests
Number of subjects: 105
Study 9048298 — intervention group
Group type: EXPERIMENTAL
Intervention: 6F Percuflex stent
Number of subjects: 60
Study 9048298 — intervention group
Group type: EXPERIMENTAL
Intervention: 6F HydroPlus stent
Number of subjects: 60
Study 9048298 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8F HydroPlus stent
Number of subjects: 60
Study 8322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg.kg‐1
Number of subjects: 123
Study 8322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1
Number of subjects: 123
Study 8322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 123
Study 8322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 123
Study 8322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone 2 mg.kg‐1
Number of subjects: 123
Study 8322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (all doses)
Number of subjects: 123
Study 8322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone and Methohexitone
Number of subjects: 123
Study 8322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 and 2.5 mg.kg‐1
Number of subjects: 123
Study 8322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturates (Thiopentone and Methohexitone)
Number of subjects: 123
Study 3709070 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia of the upper airways
Number of subjects: 11
Study 3709070 — intervention group
Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 11
Study 31566918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for childhood insomnia (CBT‐CI)
Number of subjects: 17
Study 29772190 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 30
Study 29772190 — intervention group
Group type: EXPERIMENTAL
Intervention: TMJ TJR
Number of subjects: 30
Study 29772190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental implant placement
Number of subjects: 30
Study 29772190 — intervention group
Group type: COMPARATOR
Intervention: Control group (volunteers without implanted metallic devices)
Number of subjects: 30
Study 26873055 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV (3-dose primary vaccination)
Number of subjects: 1076
Study 26873055 — intervention group
Group type: COMPARATOR
Intervention: OPV (3-dose primary vaccination)
Number of subjects: 1076
Study 26873055 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV (booster vaccination at 18-24 months)
Number of subjects: 1076
Study 26873055 — intervention group
Group type: COMPARATOR
Intervention: OPV (booster vaccination at 18-24 months)
Number of subjects: 1076
Study 26873055 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV (overall safety profile)
Number of subjects: 1076
Study 23412248 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformed lumbar microdiscectomy with curved incision and more preservation of ligamentum flavum
Number of subjects: 0
Study 23412248 — intervention group
Group type: COMPARATOR
Intervention: Traditional lumbar microdiscectomy
Number of subjects: 0
Study 22934396 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (needle-retention at Baihui (GV 20) and Sishencong (EX-HN 1), retained for 8 hours)
Number of subjects: 24
Study 22934396 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Nifedipine tablets 20 mg orally in the morning)
Number of subjects: 24
Study 20182161 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet coping skills training program
Number of subjects: 12
Study 20182161 — intervention group
Group type: COMPARATOR
Intervention: Internet education intervention
Number of subjects: 12
Study 18376092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent methylene blue therapy (Gr I, n=5)
Number of subjects: 11
Study 18376092 — intervention group
Group type: COMPARATOR
Intervention: Continuous methylene blue therapy (Gr II, n=6)
Number of subjects: 11
Study 15753425 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal DC (1 mA)
Number of subjects: 103